Click on headlines below to download research

Antiviral activity against Omicron BA.2/BA.5
Kinarus Therapeutics | 07/12/2022

Kinarus has reported that its preclinical data on lead candidate KIN001 have shown strong antiviral efficacy against SARS-CoV-2 Omicron subvariants BA.2…

USPTO allows method-of-use KIN001 patent
Kinarus Therapeutics | 24/11/2022

Kinarus received a notice of allowability from the US Patent and Trademark Office (USPTO) for its patent application No. 16/500,504 (‘methods of…

KINETIC study discontinued
Kinarus Therapeutics | 03/10/2022

Kinarus recently reported H122 financial results and reiterated its key objectives and guidance for lead candidate KIN001 in the three targeted indications,…